Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
results tags : Positive results save search
Zai Lab Presents Positive Results from Phase 3 PRIME Study of ZEJULA® (Niraparib) at Society of Gynecologic Oncology Meeting
Published: 2022-03-21 (Crawled : 01:00) - globenewswire.com
GLAXF | News | $20.2 -14.18% 510
|
Health Technology
|
| O: 4.8%
H: 4.09%
C: 4.09%
GSK | News | $40.59 2.11% -0.36% 3.8M
|
Health Technology
|
| O: 0.96%
H: 0.0%
C: 0.0%
ZLAB | $14.97 6.4% 6.01% 460K
|
Health Technology
|
| O: 10.34%
H: 0.0%
C: 0.0%
zejula pos positive results positive results phase 3 primec
Lilly, BI-Partnered Kidney Trial Stopped Early Due to Positive Results
Published: 2022-03-16 (Crawled : 17:00) - biospace.com/
LLY | News | $731.33 0.69% 0.0% 2.3M
|
Health Technology
|
| O: 0.87%
H: 0.27%
C: -0.51%
pos kidney trial positive results positive results
Junshi Biosciences and Coherus Announce Presentation of Positive Results from CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer, at March ASCO Plenary Series
Published: 2022-03-15 (Crawled : 13:30) - globenewswire.com
CHRS | $2.19 5.8% 5.48% 1.5M
|
Health Technology
|
| O: 1.41%
H: 5.81%
C: 2.53%
hoice-01 treatment pos trial presentation cel positive results asco lung cancer positive therapy bioscience results cancer phase 3
Junshi Biosciences and Coherus Announce Presentation of Positive Results from CHOICE-01
Published: 2022-03-15 (Crawled : 12:30) - biospace.com/
CHRS | $2.19 5.8% 5.48% 1.5M
|
Health Technology
|
| O: 1.41%
H: 5.81%
C: 2.53%
hoice-01 pos presentation positive results positive bioscience results
The Lancet Publishes Positive Results from Capricor Therapeutics’ Phase 2 Study Evaluating CAP-1002 in Late-Stage Duchenne Muscular Dystrophy
Published: 2022-03-11 (Crawled : 20:00) - biospace.com/
CAPR | $4.92 -1.8% -1.83% 360K
|
Health Technology
|
| O: 5.34%
H: 0.0%
C: 0.0%
cap-1002 phase 2 muscular dystrophy pos therapeutics positive results 100 duchenne positive results lancet
Coherus and Junshi Biosciences Announce Positive Results from Phase 3 Esophageal Cancer Study of Toripalimab Published in Cancer Cell
Published: 2022-03-04 (Crawled : 19:00) - biospace.com/
CHRS | $2.19 5.8% 5.48% 1.5M
|
Health Technology
|
| O: -1.56%
H: 0.0%
C: 0.0%
pos cel positive results positive bioscience results cancer phase 3
Junshi Biosciences and Coherus Announce Positive Results from Phase 3 Esophageal Cancer Study of Toripalimab Published in Cancer Cell
Published: 2022-03-04 (Crawled : 19:00) - biospace.com/
CHRS | $2.19 5.8% 5.48% 1.5M
|
Health Technology
|
| O: -1.56%
H: 0.0%
C: 0.0%
pos cel positive results positive bioscience results cancer phase 3
BioLineRx Announces Additional Positive Results from Pharmacoeconomic Study Comparing Motixafortide + G-CSF to Plerixafor + G-CSF in Stem Cell Mobilization
Published: 2022-03-03 (Crawled : 13:00) - biospace.com/
BLRX | $0.6568 0.05% 0.05% 180K
|
Health Technology
|
| O: 2.53%
H: 3.09%
C: -3.09%
cel positive results stem cell csf positive
Skye Bioscience Reports Positive Results for SBI-100 in GLP Toxicology Study
Published: 2022-02-16 (Crawled : 14:00) - biospace.com/
SKYE | $14.81 -8.24% -8.98% 220K
|
Transportation and Warehousing
|
| O: -2.11%
H: 33.85%
C: 28.62%
sbi-100 positive results 100 report positive bioscience results
NeoGenomics Liquid Biopsy Subsidiary Inivata and Collaborators Publish Positive Results from Prospective Clinical Study of RaDaR(TM) in Head and Neck Squamous Cell Carcinoma
Published: 2022-02-11 (Crawled : 08:00) - biospace.com/
NEO | $13.43 -0.74% -0.74% 800K
|
Health Services
|
| O: -1.5%
H: 0.0%
C: 0.0%
genomics genomic cel positive results positive results head and neck cell carcinoma
Inivata and Collaborators Publish Positive Results from Prospective Clinical Study of RaDaR™ in Head and Neck Squamous Cell Carcinoma
Published: 2022-02-11 (Crawled : 08:00) - biospace.com/
NEO | $13.43 -0.74% -0.74% 800K
|
Health Services
|
| O: -1.5%
H: 0.0%
C: 0.0%
cel positive results positive results head and neck cell carcinoma
Novavax Announces Positive Results of COVID-19 Vaccine in Pediatric Population of PREVENT-19 Phase 3 Clinical Trial
Published: 2022-02-10 (Crawled : 00:00) - biospace.com/
NVAX | $4.09 3.02% 2.93% 2.3M
|
Health Technology
|
| O: -4.98%
H: 0.0%
C: 0.0%
covid-19 trial covid event-19 positive results positive vaccine phase 3
SCYNEXIS Announces Positive Results from Its Pivotal Phase 3 CANDLE Study of Oral Ibrexafungerp for Prevention of Recurrent Vaginal Yeast Infections
Published: 2022-02-10 (Crawled : 13:00) - biospace.com/
SCYX | $1.47 2.08% 2.04% 73K
|
Health Technology
|
| O: -3.54%
H: 7.45%
C: 4.29%
positive results positive infection phase 3 infections
SCYNEXIS Announces Positive Results from Its Pivotal Phase 3 CANDLE Study of Oral Ibrexafungerp for Prevention of Recurrent Vaginal Yeast Infections, Clearing the Way for Regulatory Submission and Potential Approval of Additional Indication by End of 2022
Published: 2022-02-10 (Crawled : 13:00) - globenewswire.com
SCYX | $1.47 2.08% 2.04% 73K
|
Health Technology
|
| O: -3.54%
H: 7.45%
C: 4.29%
approval positive results potential positive infection phase 3 submission infections
Hoth Therapeutics Announces HT-ALZ Therapeutic Shows Positive Results - Reduce Amyloid β in Alzheimer's Disease
Published: 2022-01-04 (Crawled : 13:00) - ir.hoththerapeutics.com
HOTH | $1.21 1.21% 1.2% 15K
|
Health Technology
|
| O: 61.79%
H: 53.51%
C: 14.04%
alzheimer therapeutics disease positive results positive results alzheimer’s alzheimer's disease alzheimer's ht-alz
The Lancet Diabetes & Endocrinology Publishes Positive Results for the MPOWERED Phase 3 Trial for Mycapssa® (oral octreotide) in Acromegaly Patients
Published: 2022-01-04 (Crawled : 12:30) - globenewswire.com
AMYT | News | $14.7 0.0% 2.4M
|
Health Technology
|
| O: -1.3%
H: 0.0%
C: 0.0%
mycapssa trial diabetes positive results positive results phase 3 lancet
TRACON Pharmaceuticals Announces Positive Results from the Independent Data Monitoring Committee Review of Interim Safety and Efficacy Data from the Ongoing ENVASARC Pivotal Trial
Published: 2021-12-27 (Crawled : 14:00) - globenewswire.com
TCON | $1.8 -8.16% -8.89% 140K
|
Health Technology
|
| O: -9.47%
H: 0.0%
C: -11.82%
als ongoing trial positive results positive results
Immunic, Inc. Publishes Positive Results from the Single and Multiple Ascending Dose Parts of its Phase 1 Clinical Trial of IMU-935, a Potentially Best-in-Class Oral IL-17 Inhibitor
Published: 2021-12-14 (Crawled : 12:30) - biospace.com/
IMUX | $1.22 3.39% 3.28% 170K
|
Health Technology
|
| O: -3.49%
H: 1.75%
C: -6.36%
imu-935 trial positive results phase 1 potential positive results
Atara Biotherapeutics Announces Positive Results from Pivotal Phase 3 Trial (ALLELE) of Tab-cel® at the 63rd American Society of Hematology (ASH) Annual Meeting
Published: 2021-12-14 (Crawled : 06:00) - biospace.com/
ATRA | $0.6943 5.04% 4.8% 860K
|
Health Technology
|
| O: -4.53%
H: 4.22%
C: 2.01%
cel ema trial therapeutics positive results tab-cel positive results phase 3 iot
Allogene Therapeutics Reports Positive Results from Phase 1 UNIVERSAL Study of Single Dose ALLO-715 AlloCAR T™ Cell Therapy in Relapsed/Refractory Multiple Myeloma at the 63rd American Society of Hematology Annual Meeting
Published: 2021-12-13 (Crawled : 20:00) - biospace.com/
ALLO | $3.39 -2.31% -2.36% 1.8M
|
Health Technology
|
| O: 1.05%
H: 2.52%
C: -22.56%
allo-715 ema therapeutics positive results phase 1 positive therapy results t-cell
Gainers vs Losers
| 75% | 25% |
Top 10 Gainers
MTTR | News M | $4.78 174.71% 63.6% 72M
|
AGBA | $2.565 105.2% 51.27% 200M
|
Finance
MLEC | $2.44 74.29% 42.62% 78M
|
n/a
EDBL | News | $6.28 67.02% 40.13% 16M
|
ATGL | $2.91 48.81% 32.8% 180K
|
ZAPP | $0.2175 47.16% 32.05% 16M
|
n/a
ONFO | $0.6075 38.38% 27.74% 7.3M
|
n/a
VIVK | $1.48 38.32% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.8M
|
SDIG A | $3.635 35.13% 26.0% 1M
|
Your saved searches
Save your searches and get alerts when important news are released.